5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Highlight selection of radiochemistry and radiopharmacy developments by editorial board

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

          Main Body

          This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

          Conclusion

          Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine.

          This review is a comprehensive description of the past decade of research into understanding how the geometry and size of nanoparticles affect their interaction with biological systems: from single cells to whole organisms. Recently, there has been a great deal of effort to use both the shape and the size of nanoparticles to target specific cellular uptake mechanisms, biodistribution patterns, and pharmacokinetics. While the successes of spherical lipid-based nanoparticles have heralded marked changes in chemotherapy worldwide, the history of asbestos-induced lung disease casts a long shadow over fibrous materials to date. The impact of particle morphology is known to be intertwined with many physicochemical parameters, namely, size, elasticity, surface chemistry, and biopersistence. In this review, we first highlight some of the morphologies observed in nature as well as shapes available to us through synthetic strategies. Following this we discuss attempts to understand the cellular uptake of nanoparticles through various theoretical models before comparing this with observations from in vitro and in vivo experiments. In addition, we consider the impact of nanoparticle shape at different size regimes on targeting, cytotoxicity, and cellular mechanics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            (64)Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

            Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an explanation for variable responses to therapeutic nanoparticles in clinical studies.Experimental Design: We assessed the EPR effect in patients using a (64)Cu-labeled nanoparticle, (64)Cu-MM-302 ((64)Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), and imaging by PET/CT. Nineteen patients with HER2-positive metastatic breast cancer underwent 2 to 3 PET/CT scans postadministration of (64)Cu-MM-302 as part of a clinical trial of MM-302 plus trastuzumab with and without cyclophosphamide (NCT01304797).Results: Significant background uptake of (64)Cu-MM-302 was observed in liver and spleen. Tumor accumulation of (64)Cu-MM-302 at 24 to 48 hours varied 35-fold (0.52-18.5 %ID/kg), including deposition in bone and brain lesions, and was independent of systemic plasma exposure. Computational analysis quantified rates of deposition and washout, indicating peak liposome deposition at 24 to 48 hours. Patients were classified on the basis of (64)Cu-MM-302 lesion deposition using a cut-off point that is comparable with a response threshold in preclinical studies. In a retrospective exploratory analysis of patient outcomes relating to drug levels in tumor lesions, high (64)Cu-MM-302 deposition was associated with more favorable treatment outcomes (HR = 0.42).Conclusions: These findings provide important evidence and quantification of the EPR effect in human metastatic tumors and support imaging nanoparticle deposition in tumors as a potential means to identify patients well suited for treatment with therapeutic nanoparticles. Clin Cancer Res; 1-13. ©2017 AACR.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy

                Bookmark

                Author and article information

                Contributors
                toyohara@pet.tmig.or.jp
                moqahtani@kfshrc.edu.sa
                care.huang@primobt.com
                emiliano.cazzola@sacrocuore.it
                sergio.todde@unimib.it
                shozo.furumoto.b6@tohoku.ac.jp
                Renata.Mikolajczak@polatom.pl
                Clemens.Decristoforo@tirol-kliniken.at
                nicholas.mathew.gillings@regionh.dk
                yangmin@jsinm.org
                raymond.reilly@utoronto.ca
                dta@unife.it
                G.Denkova@tudelft.nl
                schirrma@ualberta.ca
                gcarlucci@mednet.ucla.edu
                y.seimbille@erasmusmc.nl
                liuzf@bjmu.edu.cn
                Bev.Ellis@mft.nhs.uk
                b.t.cornelissen@umcg.nl
                k.kopka@hzdr.de
                emerson.bernardes@gmail.com
                Journal
                EJNMMI Radiopharm Chem
                EJNMMI Radiopharm Chem
                EJNMMI Radiopharmacy and Chemistry
                Springer International Publishing (Cham )
                2365-421X
                1 October 2022
                1 October 2022
                December 2022
                : 7
                : 25
                Affiliations
                [1 ]GRID grid.420122.7, ISNI 0000 0000 9337 2516, PET Radiopharmaceutical Sciences, Research Team for Neuroimaging, , Tokyo Metropolitan Institute of Gerontology, ; Tokyo, Japan
                [2 ]GRID grid.415310.2, ISNI 0000 0001 2191 4301, Cyclotron and Radiopharmaceuticals Department, , King Faisal Specialist Hospital and Research Center (KFSHRC), ; Riyadh, Saudi Arabia
                [3 ]GRID grid.19188.39, ISNI 0000 0004 0546 0241, Molecular Imaging Center, , National Taiwan University, ; Taipei, Taiwan
                [4 ]Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Sacro Cuore-Don Calabria Hospital, Negrar (Vr), Italy
                [5 ]GRID grid.414603.4, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Sacro Cuore-Don Calabria, ; Negrar (Vr), Italia
                [6 ]GRID grid.7563.7, ISNI 0000 0001 2174 1754, University of Milano-Bicocca, Tecnomed Foundation, ; Monza, Italy
                [7 ]GRID grid.69566.3a, ISNI 0000 0001 2248 6943, Cyclotron and Radioisotope Center (CYRIC), , Tohoku University, ; Sendai, Japan
                [8 ]GRID grid.450295.f, ISNI 0000 0001 0941 0848, Radioisotope Centre POLATOM, , National Centre for Nuclear Research (NCBJ), ; Otwock, Poland
                [9 ]GRID grid.450295.f, ISNI 0000 0001 0941 0848, Ośrodek Radioizotopów POLATOM, , NARODOWE CENTRUM BADAŃ JĄDROWYCH (NCBJ), ; Otwock, Poland
                [10 ]GRID grid.5361.1, ISNI 0000 0000 8853 2677, Department of Nuclear Medicine, , Medical University of Innsbruck, ; Innsbruck, Austria
                [11 ]GRID grid.475435.4, Department of Clinical Physiology and Nuclear Medicine, , Copenhagen University Hospital Rigshospitalet, ; Copenhagen, Denmark
                [12 ]GRID grid.412676.0, ISNI 0000 0004 1799 0784, NHC Key Laboratory of Nuclear Medicine, , Jiangsu Institute of Nuclear Medicine, ; Wuxi, Jiangsu China
                [13 ]GRID grid.17063.33, ISNI 0000 0001 2157 2938, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, , University of Toronto, ; Toronto, ON Canada
                [14 ]GRID grid.8484.0, ISNI 0000 0004 1757 2064, Department of Chemical, Pharmaceutical and Agricultural Sciences, , University of Ferrara, ; Ferrara, Italy
                [15 ]GRID grid.8484.0, ISNI 0000 0004 1757 2064, Dipartimento di Scienze Chimiche, , Farmaceutiche e Agrarie Università di Ferrara, ; Ferrara, Italia
                [16 ]GRID grid.5292.c, ISNI 0000 0001 2097 4740, Department of Radiation Science and Technology, , Delft University of Technology, ; Delft, The Netherlands
                [17 ]GRID grid.17089.37, ISNI 0000 0001 2190 316X, Department of Oncology, Cross Cancer Institute, , University of Alberta, ; Edmonton, AB Canada
                [18 ]GRID grid.19006.3e, ISNI 0000 0000 9632 6718, Department of Molecular and Medical Pharmacology, , University of California, Los Angeles (UCLA), ; Los Angeles, CA USA
                [19 ]GRID grid.5645.2, ISNI 000000040459992X, Department of Radiology and Nuclear Medicine, Erasmus MC, , University Medical Center Rotterdam, ; Rotterdam, The Netherlands
                [20 ]GRID grid.11135.37, ISNI 0000 0001 2256 9319, Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, , Peking University Health Science Centre, ; Beijing, China
                [21 ]GRID grid.498924.a, ISNI 0000 0004 0430 9101, Manchester University NHS Foundation Trust, ; Manchester, UK
                [22 ]GRID grid.4830.f, ISNI 0000 0004 0407 1981, Department of Nuclear Medicine and Molecular Imaging, Groningen (UMCG), , University Medical Center, University of Groningen, ; Groningen, The Netherlands
                [23 ]GRID grid.40602.30, ISNI 0000 0001 2158 0612, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, ; Dresden, Germany
                [24 ]GRID grid.466806.a, ISNI 0000 0001 2104 465X, Energy and Nuclear Research Institute (IPEN-CNEN/SP), Cidade Universitária, ; São Paulo, Brazil
                [25 ]GRID grid.466806.a, ISNI 0000 0001 2104 465X, Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/SP), Cidade Universitária, ; São Paulo, Brasil
                Author information
                http://orcid.org/0000-0003-4846-1271
                Article
                177
                10.1186/s41181-022-00177-w
                9526771
                36182995
                77a1f4cd-c893-4906-bfd4-f17fde797828
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 12 August 2022
                : 5 September 2022
                : 7 September 2022
                Funding
                Funded by: Helmholtz-Zentrum Dresden - Rossendorf e. V. (4213)
                Categories
                Review
                Custom metadata
                © The Author(s) 2022

                highlight articles,radiochemistry,radiopharmacy,radiopharmaceutical sciences,nuclear medicine,trends in radiopharmaceutical sciences

                Comments

                Comment on this article